PDCD1 and nasopharyngeal carcinoma: A phase I trial investigating the efficacy of camrelizumab, a humanized anti-PD1 antibody, in patients with metastatic NPC, 9/45 patients (ORR 20.5%) achieved favorable response with 59% 1-year overall survival (OS).